Daryl brings a background spanning R&D, value demonstration, market access and commercialization for a range of health technologies including small molecules and biologicals, regenerative medicines, precision medicine, medical devices, and e-connective technologies. He has experience across multiple therapeutic areas, including oncology, neurology, cardiovascular, respiratory, immunology, metabolic, and genetic and rare diseases. His work has spanned government, industry and consulting sectors, and he has over 60 publications, conference presentations, and abstracts.
Daryl has served on health policy leadership groups related to HTA, HEOR, and market access, including for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Academy of Managed Care Pharmacy (AMCP), National Association of Managed Care Physicians (NAMCP), and other professional associations. He was part of the ISPOR group leadership issuing recommendations on global harmonization of diagnostic HTA processes, the AMCP working group issuing the first guidance to manufacturers on incorporating companion diagnostics evidence into the AMCP Format for Formulary Submissions, and the NAMCP Genomics, Biotech and Emerging Medical Technologies Institute
Prior to Evidera, Daryl was Senior Director of Managed Care and Reimbursement at Courtagen Life Sciences, a next generation sequencing-based genetic testing company. At Courtagen, he developed and led company-wide market access and commercial strategies, including engagement with HTA agencies, payers, providers, and customer groups. Prior to Courtagen, he was an Associate Practice Lead, and Principal Consultant at Quintiles Advisory Services, where his specialty included value demonstration and global market access of emerging health technologies. Prior to joining Quintiles, Daryl was an Associate Director in RTI Health Solutions’ Market Access and Outcomes Strategy advisory practice helping to build a global market access function for the company.
Before his consulting career, Daryl was Research Group Leader, Lab Director and faculty at the New York State Institute for Basic Research in Staten Island, New York, where he directed a translational research program covering diagnostics and therapeutics for Alzheimer’s, prion disease and autism spectrum disorders. While a scientist, he developed a number of products out-licensed to biotechnology companies for drug and diagnostic R&D.
Daryl earned a BS (Hons) in Chemistry, and a PhD in Molecular and Cellular Pharmacology from the State University of New York at Stony Brook, and an MBA in Finance, and Health Sector Management from Duke University’s Fuqua School of Business.